BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35048154)

  • 1. Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study.
    Deng J; Zhong Y; Wang T; Yang M; Ma M; Song Y; She Y; Chen C;
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2414-2424. PubMed ID: 35048154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.
    Akthar AS; Ferguson MK; Koshy M; Vigneswaran WT; Malik R
    Technol Cancer Res Treat; 2017 Feb; 16(1):15-21. PubMed ID: 26792491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer.
    Zhong Y; Cai C; Chen T; Gui H; Deng J; Yang M; Yu B; Song Y; Wang T; Sun X; Shi J; Chen Y; Xie D; Chen C; She Y
    Nat Commun; 2023 Nov; 14(1):7513. PubMed ID: 37980411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Endosonographic Mediastinal Lymph Node Staging in Positron Emission Tomography and Computed Tomography Node-Negative Non-Small-Cell Lung Cancer in High-Risk Patients.
    Hegde P; Molina JC; Thivierge-Southidara M; Jain RV; Gowda A; Ferraro P; Liberman M
    Semin Thorac Cardiovasc Surg; 2020; 32(1):162-168. PubMed ID: 31325576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
    Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative identification of clinicopathological prognostic factors for relapse-free survival in clinical N1 non-small cell lung cancer: a retrospective single center-based study.
    Aragaki M; Kato T; Fujiwara-Kuroda A; Hida Y; Kaga K; Wakasa S
    J Cardiothorac Surg; 2020 Aug; 15(1):229. PubMed ID: 32859238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
    Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
    BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated positron emission tomography and computed tomography in preoperative lymph node staging of non-small cell lung cancer.
    Xu N; Wang M; Zhu Z; Zhang Y; Jiao Y; Fang W
    Chin Med J (Engl); 2014; 127(4):607-13. PubMed ID: 24534208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.
    De Leyn P; Stroobants S; De Wever W; Lerut T; Coosemans W; Decker G; Nafteux P; Van Raemdonck D; Mortelmans L; Nackaerts K; Vansteenkiste J
    J Clin Oncol; 2006 Jul; 24(21):3333-9. PubMed ID: 16849747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Misstagings and Risk Factors of Occult Nodal Disease in Non-Small Cell Lung Cancer.
    Dyas AR; King RW; Ghanim AF; Cerfolio RJ
    Ann Thorac Surg; 2018 Nov; 106(5):1492-1498. PubMed ID: 29908981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2.
    Pahk K; Chung JH; Yi E; Kim S; Lee SH
    Eur J Radiol; 2018 Sep; 106():145-149. PubMed ID: 30150037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetected lymph node metastases in presumed early stage NSCLC SABR patients.
    Cerra-Franco A; Diab K; Lautenschlaeger T
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):869-75. PubMed ID: 27279087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
    BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prognostic values of primary tumor and nodal
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.